{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T03:39:08Z","timestamp":1773027548783,"version":"3.50.1"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005725","name":"CHDI Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","prd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Parkinsonism &amp; Related Disorders"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.parkreldis.2021.10.013","type":"journal-article","created":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T05:03:00Z","timestamp":1634274180000},"page":"89-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Validation of biomarkers in Huntington disease to support the development of disease-modifying therapies: A systematic review and critical appraisal scheme"],"prefix":"10.1016","volume":"93","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-8609","authenticated-orcid":false,"given":"Hanna","family":"Tang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thilo","family":"van Eimeren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Sampaio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiago A.","family":"Mestre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.parkreldis.2021.10.013_bib1","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/mdc3.12808","article-title":"Movement disorder society task force viewpoint: Huntington's disease diagnostic categories","volume":"6","author":"Ross","year":"2019","journal-title":"Mov Disord Clin Pr"},{"key":"10.1016\/j.parkreldis.2021.10.013_bib2","series-title":"F.-N.B.W. Group, No Title, in: BEST (Biomarkers, EndpointS, Other Tools) Resour","year":"2016"},{"key":"10.1016\/j.parkreldis.2021.10.013_bib3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1399-0004.2004.00241.x","article-title":"A\u00a0new model for prediction of the age of onset and penetrance for Huntington's disease based on CAG length","volume":"65","author":"Langbehn","year":"2004","journal-title":"Clin. Genet."},{"key":"10.1016\/j.parkreldis.2021.10.013_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/ajmg.b.30992","article-title":"CAG-repeat length and the age of onset in Huntington disease (HD): a review and validation study of statistical approaches","volume":"153B","author":"Langbehn","year":"2010","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"key":"10.1016\/j.parkreldis.2021.10.013_bib5","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1212\/01.wnl.0000261918.90053.96","article-title":"Predictors of diagnosis in Huntington disease","volume":"68","author":"Langbehn","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.parkreldis.2021.10.013_bib6","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1373\/49.1.7","article-title":"The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration","volume":"49","author":"Bossuyt","year":"2003","journal-title":"Clin. Chem."},{"key":"10.1016\/j.parkreldis.2021.10.013_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088854","article-title":"A\u00a0systematic review of biomarkers for disease progression in Alzheimer's disease","volume":"9","author":"McGhee","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.parkreldis.2021.10.013_bib8","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1471-2377-13-35","article-title":"A\u00a0systematic review of biomarkers for disease progression in Parkinson's disease","volume":"13","author":"McGhee","year":"2013","journal-title":"BMC Neurol."},{"key":"10.1016\/j.parkreldis.2021.10.013_bib9","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.dadm.2019.01.011","article-title":"Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: proposal for a Neuroimaging Biomarker Utility System","volume":"11","author":"van Eimeren","year":"2019","journal-title":"Alzheimers Dement (Amst)"},{"key":"10.1016\/j.parkreldis.2021.10.013_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/2046-4053-4-1","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement","volume":"4","author":"Moher","year":"2015","journal-title":"Syst. Rev."}],"container-title":["Parkinsonism &amp; Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021003680?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1353802021003680?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T00:24:28Z","timestamp":1761179068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1353802021003680"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":10,"alternative-id":["S1353802021003680"],"URL":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.10.013","relation":{},"ISSN":["1353-8020"],"issn-type":[{"value":"1353-8020","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Validation of biomarkers in Huntington disease to support the development of disease-modifying therapies: A systematic review and critical appraisal scheme","name":"articletitle","label":"Article Title"},{"value":"Parkinsonism & Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.parkreldis.2021.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}